Match Document Document Title
US20140271780 PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT  
Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions...
US20110046136 METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH  
The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of...
US20140093592 ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION  
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a...
US20130236573 ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION  
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a...
US20140294986 Microsphere Drug Delivery System for Sustained Intraocular Release  
Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres...
US20120238601 TREATMENT OF CANCER  
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer...
US20150119383 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130245004 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130143867 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130317078 PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES  
The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propy nyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions...
US20120029048 PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES  
The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propy nyl]-N-hydroxyurea for treatment of leukotriene related pathologies and compositions...
US20150196531 Methods and Compositions For Treating Sleep-Related Breathing Disorders  
Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine.
US20120238616 METHODS AND COMPOSITIONS FOR TREATING SLEEP-RELATED BREATHING DISORDERS  
Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine.
US20150118309 PREPARATION FOR PERCUTANEOUS ABSORPTION CONTAINING ROTIGOTINE  
Exemplary embodiments of the present invention relate to a method for preparing a preparation for percutaneous absorption, which includes rotigotine as an active ingredient, and more specifically,...
US20110245264 Modulators of G Protein-Coupled Receptor 88  
The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled...
US20100317627 Treatment of HCV Disorders  
S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).
US20130344116 Oral particle consisting of an amorphous structure and a submicron domain  
The present invention relates to compositions and methods of the preparation of an oral particle essentially consisting of an amorphous structure and a submicron domain, wherein both amorphous...
US20110104281 METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND  
A method for treating pain, particularly non-inflammatory musculoskeletal pain such as myofascial pain or back pain, in a subject comprises administering to the subject a substituted...
US20120322769 METHODS OF REDUCING VIRULENCE IN BACTERIA  
A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising...
US20130109674 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TRIGEMINAL AUTONOMIC CEPHALGIAS, MIGRAINE, AND VASCULAR CONDITIONS  
The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with...
US20100331388 Crystalline Duloxetine Hydrochloride  
Crystalline duloxetine hydrochloride, compositions containing the same and methods for the production thereof.
US20140155369 PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME  
An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress...
US20140255488 LONG ACTING SUSTAINED-RELEASE FORMULATION CONTAINING DOPAMINE RECEPTOR AGONIST AND THE PREPARATION METHOD THEREOF  
The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable...
US20130252964 Compounds And Methods For Treating Candidiasis And Aspergillus Infections  
The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal...
US20140377365 SUSTAINED-RELEASE FORMULATION OF ROTIGOTINE  
Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and...
US20080146622 Use Of Substituted 2-Aminotetralins For Preventive Treatment Of Parkinson's Disease  
The invention relates to the use of substituted 2-aminotetralins of general formula (I) as a medicament for the preventive treatment of Parkinson's disease.
US20110092517 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases  
Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory...
US20130165493 Antiviral Drugs for Treatment of Arenavirus Infection  
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing...
US20120149751 Antiviral Drugs for Treatment of Arenavirus Infection  
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing...
US20120149693 THERAPEUTIC COMPOUNDS  
The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for...
US20110152315 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES  
There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in...
US20130324585 ROTIGOTINE IONIC LIQUID  
The present invention provides ionic liquids of rotigotine, pharmaceutical compositions comprising said ionic liquids and methods of preparing such ionic liquids. The invention further provides...
US20110020439 DELAYED RELEASE COMPOSITIONS OF DULOXETINE  
A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s)...
US20120232031 INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION  
Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for...
US20110028453 Treating Negative Symptoms of Schizophrenia Associated with Defective Neuregulin 1  
Use of a compound that is a serotonin transporter inhibitor, a selective norepinephrine reuptake inhibitor, or a 5-HT1A agonist for alleviating negative symptoms in a schizophrenia patient who...
US20110274750 ENTERIC FORMULATION OF DULOXETINE AND ITS CORE AND PREPRATION METHOD  
An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients...
US20130039854 MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER  
A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer...
US20110152322 Aminopropenoates as Fungicides  
The present invention relates to aminopropenoate derivatives, the process of their preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide...
US20140309274 Lipidic Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders  
Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective...
US20110106241 COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE  
Amidine analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumor cells.
US20110104162 Compounds which can be used for the Treatment of Cancers  
The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in...
US20140135374 Opsin-Binding Ligands, Compositions and Methods of Use  
Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular...
US20090326607 Electrical Stimulation Method for Treatment of Peripheral Neuropathy  
An electrical stimulation method for the treatment of peripheral neuropathy is disclosed. In a preferred embodiment, the method utilizes an electrical stimulation device that includes a plurality...
US20150080386 Compounds For The Treatment Of Proliferative Disorders  
Disclosed are compounds and pharmaceutical compositions that are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical...
US20140378917 TRANSDERMAL THERAPEUTIC SYSTEM WITH A LOW TENDENCY TO SPONTANEOUSLY CRYSTALLIZE  
The present invention provides transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The...
US20140315965 BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER  
The present disclosure relates to novel compounds having vitamin D receptor agonist and histone deacetylase inhibitory efficacy as well as methods for reducing or inhibiting the proliferation of...
US20120322845 POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE  
The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine,...
US20140275179 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES  
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula...
US20120122870 Treatment Of Ischemia-Reperfusion Injury  
Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no...
US20110251175 Stigmine Conjugates for Substance Use Disorders  
The invention relates to methods for the treatment or prevention of substance use disorders.